Search research articles
Contact Us
Filters
Showing results (141-150 of 154) with videos related to
Page
of 16
Sort By:
Oncogene
|
November 13, 2001
p73 Overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis
F Vikhanskaya, M R Bani, P Borsotti, et al.
Cancer Research
|
February 15, 1987
Prostaglandin and thromboxane synthesis by M5076 ovarian reticulosarcoma during growth: effects of a thromboxane synthetase inhibitor
C Chiabrando, M Broggini, M G Castelli, et al.
Cancer Treatment Reports
|
August 1, 1980
Early phase pharmacokinetics of doxorubicin (adriamycin) in plasma of cancer patients during single- or multiple-drug therapy
E Piazza, M G Donelli, M Broggini, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 22, 2005
Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743
S Marchini, E Marrazzo, R Bonomi, et al.
British Journal of Cancer
|
January 7, 2010
A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate
M Falasca, D Chiozzotto, H Y Godage, et al.
Cancer Research
|
September 24, 1999
Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer
P Fullwood, S Marchini, J S Rader, et al.
Leukemia
|
January 17, 2003
Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4
M Broggini, S V Marchini, E Galliera, et al.
British Journal of Cancer
|
January 1, 1997
DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status
P De Feudis, D Debernardis, P Beccaglia, et al.
British Journal of Cancer
|
August 14, 2003
Effect of Aplidin in acute lymphoblastic leukaemia cells
E Erba, M Serafini, G Gaipa, et al.
Reumatismo
|
October 31, 2002
[Sodium gold thiosulfate therapy: an open, viewed, multicenter trial in rheumatoid arthritis patients followed for two years]
M L Ciompi, C Amoresano, P Balzarini, et al.
Page
of 16
Search research articles
Search
Showing results (141-150 of 154) with videos related to
Sort By:
Page
of 16
Oncogene
|
November 13, 2001
p73 Overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis
F Vikhanskaya, M R Bani, P Borsotti, et al.
Cancer Research
|
February 15, 1987
Prostaglandin and thromboxane synthesis by M5076 ovarian reticulosarcoma during growth: effects of a thromboxane synthetase inhibitor
C Chiabrando, M Broggini, M G Castelli, et al.
Cancer Treatment Reports
|
August 1, 1980
Early phase pharmacokinetics of doxorubicin (adriamycin) in plasma of cancer patients during single- or multiple-drug therapy
E Piazza, M G Donelli, M Broggini, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 22, 2005
Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743
S Marchini, E Marrazzo, R Bonomi, et al.
British Journal of Cancer
|
January 7, 2010
A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate
M Falasca, D Chiozzotto, H Y Godage, et al.
Cancer Research
|
September 24, 1999
Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer
P Fullwood, S Marchini, J S Rader, et al.
Leukemia
|
January 17, 2003
Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4
M Broggini, S V Marchini, E Galliera, et al.
British Journal of Cancer
|
January 1, 1997
DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status
P De Feudis, D Debernardis, P Beccaglia, et al.
British Journal of Cancer
|
August 14, 2003
Effect of Aplidin in acute lymphoblastic leukaemia cells
E Erba, M Serafini, G Gaipa, et al.
Reumatismo
|
October 31, 2002
[Sodium gold thiosulfate therapy: an open, viewed, multicenter trial in rheumatoid arthritis patients followed for two years]
M L Ciompi, C Amoresano, P Balzarini, et al.
Page
of 16